Skip to content
Exclusive CEO Interviews
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

✨ Onyx Summary Lexicon Pharmaceuticals announced the publication of preclinical data in the Journal of the Endocrine Society validating Acyl-CoA Synthetase 5 (ACSL5) as a therapeutic target for obesity and chronic weight management, supporting advancement of its investigational oral inhibitor LX9851. The findings, combined with Lexicon’s March 2025 worldwide

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

✨ Onyx Summary Geron presented new ASH 2025 data reinforcing RYTELO (imetelstat) activity in lower-risk MDS and myelofibrosis, including analyses linking early treatment-emergent cytopenias to subsequent hemoglobin gains and transfusion independence in the IMerge program. Updated long-term outcomes from IMerge and biomarker findings from IMbark further support ongoing

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

✨ Onyx Summary Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial showing that REC-4881, an investigational allosteric MEK1/2 inhibitor, delivered rapid and durable reductions in polyp burden in patients with familial adenomatous polyposis, with effects persisting after treatment cessation. The results represent the first clinical

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

✨ Onyx Summary Legend Biotech Corporation reported updated ASH 2025 data showing CARVYKTI® achieved a median progression-free survival of 50.4 months in triple-class-exposed multiple myeloma patients with three prior lines of therapy, with translational analyses indicating stronger immune fitness when used earlier in treatment. The company also

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

✨ Onyx Summary Lexicon Pharmaceuticals announced that new clinical data from the SOTA-P-CARDIA trial evaluating the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients with HFpEF will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum in December 2025. The presentation adds to prior

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

✨ Onyx Summary Guardant Health will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium (Dec. 9–12, 2025) highlighting data across Guardant Reveal and Guardant360 Liquid that evaluate tissue-free, blood-based testing for minimal residual disease detection, treatment response assessment, relapse risk prediction, and breast cancer subtyping

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

✨ Onyx Summary Perspective Therapeutics announced that updated safety and preliminary efficacy data from its [212Pb]VMT-α-NET program in advanced SSTR2-expressing neuroendocrine tumors have been accepted for presentation at the ASCO Gastrointestinal Cancers Symposium 2026. The accepted abstract builds on previously reported interim results showing a favorable safety

VeriSIM Life Wins Prestigious AI in Action Award at Reuters Global Pharma Awards

VeriSIM Life Wins Prestigious AI in Action Award at Reuters Global Pharma Awards

✨ Onyx Summary VeriSIM Life was named the winner of the AI in Action Award at the Reuters Global Pharma Awards 2025 for its BIOiSIM platform, which applies explainable, mechanistic AI to predict human safety, efficacy, and translational outcomes earlier in drug development. The recognition highlights VeriSIM Life’s growing role

MassBio and SCbio launch Drive application for spring cohort

MassBio and SCbio launch Drive application for spring cohort

✨ Onyx Summary MassBio and SCbio opened applications for the Spring 2026 cohort of Drive, a national accelerator for early-stage biotech and biomarker/diagnostic startups, with programs running March 23–May 15, 2026 and an application deadline of January 16, 2026. The announcement reflects continued investment in early scientific founders,

Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease

Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease

✨ Onyx Summary Alzheon, Inc. announced a peer-reviewed publication in CNS Drugs synthesizing evidence that hippocampal volume on MRI tracks cognitive decline and therapeutic response in early symptomatic Alzheimer’s disease, supporting its use as a surrogate marker in clinical development. The review proposes a hippocampal volume preservation threshold (≥40

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

✨ Onyx Summary Belite Bio commenced an underwritten public offering of ADSs, with all shares sold by the company and an additional 30-day underwriter option for extra ADSs, subject to market conditions. Proceeds are earmarked for commercialization buildout, pipeline development and expansion, and general corporate purposes, with Morgan Stanley, Leerink,

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

✨ Onyx Summary Belite Bio reported positive topline Phase 3 DRAGON results showing its oral therapy tinlarebant met the primary endpoint in Stargardt disease type 1, delivering a statistically significant 35.7% reduction in retinal lesion growth versus placebo over 24 months in 104 adolescent patients. The company said the safety

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

✨ Onyx Summary Recursion announced it will host a December 8, 2025 company webinar to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial evaluating REC-4881 monotherapy in patients with familial adenomatous polyposis, including new safety and efficacy data. Salt Lake City, Dec. 01, 2025 – Recursion